Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
This pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR
(Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC
lung disease. This study will enroll adult patients with treatment-refractory MAC lung
...
Age: 18 years - 66+
Gender: All
PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.
A 3-year cluster randomized controlled trial of the impact of a quality improvement and
clinical decision support package versus usual care for patients with modifiable high-risk
chronic obstructive pulmonary disease with or without a current diagnosis.
Age: 18 years - 66+
Gender: All
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of
BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib...
Age: 18 years - 66+
Gender: All
Comparative Effectiveness of Telemedicine in Primary Care
Leveraging a natural experiment approach, the investigators will examine rapidly changing
telemedicine and in-person models of care during and after the COVID-19 crisis to determine
whether certain patients could safely choose to continue telemedicine or
telemedic...
Age: 19 years - 66+
Gender: All
Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)
A multi-center, randomized, 72-month, parallel- group, non-inferiority, phase III study to
compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate
regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or al...
Age: 40 years - 66+
Gender: All
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants
with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
Age: 18 years - 66+
Gender: All
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of
ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or
PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Age: 18 years - 66+
Gender: All